AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03942848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo followed by zicotinide
Description: The placebo treatment period consists in standard saline solution (preservative-free sodium chloride 9 milligram/milliliter (mg/ml) (0.9%) solution) which will be presented exactly in vials as presented for the treatment (volume, color, shape et size of the vial). Treating physicians will not be aware of the actual contents of the pump and will increase the volume of injected placebo as a treatment solution (as Ziconotide 10 micrograms/milliliter (μg/ml). The magnitude of increase is the decision of the treating physician (as long as it remains with the recommended limits by the Hospital Anxiety and Depression Scale (HAS) but most likely augmentations will be at maximum 1 microgram per month and maximum achieved doses allowed in SPIDOL study is 20 micrograms/day (in literature approximately 75% of patients who respond satisfactorily to treatment required a dose of ≤ 9.6 micrograms/day
Study NCT00540826 — intervention group
Intervention type: DRUG
Intervention: Atomoxetine
Description: in-label use
Study NCT00540826 — intervention group
Intervention type: DRUG
Intervention: stimulants (any approved ADHD medication)
Description: in-label use
Study NCT01259908 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic vs open Ygraft
Description: Patients with aorto-iliac occlusive disease TASC type D operated with either laparoscopic aortobifemoral bypass or open aortobifemoral bypass shall be compared.
Study NCT01103791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel-PNP
Description: Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel
Study NCT04140591 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Proton-pump inhibitor
Description: PPI: Pariet EC 20mg/QDAC
Study NCT04140591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol+Proton-pump inhibitor
Description: Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure >90mmHg) PPI: Pariet EC 20mg/QDAC
Study NCT03649750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucinex®
Description: Mucinex® 600 mg ER bi-layer tablets
Study NCT01258790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Repetitive Transcranial Magnetic Stimulation
Description: Repetitive Transcranial Magnetic Stimulation (RTMS) is a relatively new technology that allows for targeted noninvasive stimulation of the brain. RTMS is currently FDA-cleared for the treatment of refractory depression. It is also used experimentally to treat seizures, spasticity, dystonia and other neuropsychiatric conditions. The Active intervention uses an active magnetic coil.
Study NCT00883818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin, doxycycline
Description: azithromycin 1g once for women with positive cultures at baseline~doxycycline 100 mg twice daily for 7 days for women with persistent infection after treatment of azithromycin 1g
Study NCT02241733 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing retraining plus exercise
Description: Patients will participate in a 12-week exercise program with breathing retraining. They will also participate in an adherence program.
Study NCT02241733 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise only
Description: Patients will participate in a 12-week exercise program . They will also participate in an adherence program.
Study NCT00671892 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide endotoxin
Description: Delivered in nebulized form expressed in activity units(endotoxin units -EU).~Subjects receive each dose 30 min after completing the previous dose, dose duration is approximately 10 minutes:~Challenge One first saline then 5000 EU 10,000 EU 20,000 EU~Challenge 1 and 2 must be at least 2 weeks apart.~Challenge 2 Saline 40,000 EU 80,000 EU
Study NCT03459248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual therapy
Description: combination of 10 mg metoclopramide with 4 mg ondansetron
Study NCT03459248 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monotherapy
Description: 10 mg metoclopramide
Study NCT03459248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: Induction of general anesthesia will be performed followed by endotracheal intubation.
Study NCT03459248 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Induction of general anesthesia will be performed followed by endotracheal intubation.
Study NCT03081065 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Nutritional advice to follow a Mediterranean diet and supplementation with extra virgin olive oil and nuts
Study NCT02915276 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blastocentisis
Description: Removal of blastocoelic fluid from the blastocoelic cavity
Study NCT02915276 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trophectoderm biopsy
Description: Removal of trophectoderm cells from the blastocyst
Study NCT04802460 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality headset (The Guided Meditation VR App through Oculus Go headset)
Description: Patients assigned to the VR condition will engage with the VR using The Guided Meditation VR App through Oculus Go headset. They will enjoy up to a 10 minute video of an environment of their choosing. During this video they will listen to calming music and a guided meditation session.
Study NCT02176330 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ePAQ-PF followed by a telephone consultation.
Description: All women randomised to this arm of the study were entered onto the hospital electronic patient record system under the ePAQ clinic. They were were posted an information letter and an epaq-online voucher inviting them to complete the questionnaire on-line. The clinician used these results along with the patient's own casenotes and original referral letter to support the subsequent consultation. The research nurse (HJW) then arranged their telephone consultation. Women in this group who felt unable to complete the questionnaire online would use this telephone call with the research nurse to make arrangements to attend and complete the questionnaire at the hospital.
Study NCT02176330 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ePAQ-PF followed by a face to face consultation
Description: All women randomised to this arm of the study were posted an appointment to attend the urogynaecology clinic. They were were posted an information letter and an epaq-online voucher inviting them to complete the questionnaire on-line. The clinician used these results along with the patient's own casenotes and original referral letter to support the subsequent consultation. Women then attended for their face to face clinic consultation as normal. Women in this group who felt unable to complete the questionnaire online were given the opportunity to complete the questionnaire at the hospital when they attended for their consultation.
Study NCT02299297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Dosage/Frequency: 5mg - 10mg, oral, twice daily
Study NCT03951844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BRIDGE/EMPATIA exoskeleton
Description: The participant wears the exoskeleton on his/her left arm, and he/she controls it by means of a joystick or vocal commands.
Study NCT03789318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CA-008 5 mg
Description: 5 mg CA-008 reconstituted in saline.
Study NCT03789318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each cohort will use placebo reconstituted in saline.
Study NCT03789318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 0.25% administered pre-surgery
Study NCT03789318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 0.25% administered pre-surgery
Study NCT00192218 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist
Description: 0.5 ml of vaccine intranasally (0.25 ml in each nostril) which contains approximately 107 TCID50 of each type
Study NCT01908491 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IV PCA
Description: On arrival in the postanesthetic care unit, a patient-controlled analgesia (IV PCA) was connected to the iv catheter. The PCA regimen consisted of hydromorphone (2 mcg/kg/hr) and ketorolac (0.02 mg/kg/hr) with normal saline (total volume 100ml). PCA was programmed to deliver 1 ml/hr as background infusion and 1 ml per demand with a 10 min lockout during 48 hr period.
Study NCT03107169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMT
Description: Patients in the FMT group received FMT-FURM
Study NCT03107169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: Patients in the vancomycin group received oral vancomycin (250 mg every 6 h for 10-14 days)
Study NCT01908491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous wound infusion
Description: Patients underwent insertion of wound catheters by the surgeon just before the closure of incision site. The wound catheters, consisting of double branch and connected to elastomeric pump filled with ropivacaine (0.15\~0.25%) and administered at a constant flow rate of 2 ml/hr in each branch of the catheter for 48 hr.
Study NCT02218697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influsplit™ Tetra (Fluarix™ Tetra)
Description: Intramuscular injection, 1 dose each in Control and Co-Ad groups.
Study NCT03789318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: 0.02 mg/kg IV administered intraoperatively
Study NCT03789318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydromorphone
Description: 0.02 mg/kg IV administered intraoperatively
Study NCT03789318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 100 mcg IV administered intraoperatively
Study NCT03789318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: 100 mcg IV administered intraoperatively
Study NCT02218697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax™ 23
Description: Intramuscular injection, 1 dose each in Control and Co-Ad groups.
Study NCT02218697 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo (Saline)
Description: Intramuscular injection, 1 dose each in Control and Co-Ad groups.
Study NCT03430024 — intervention group
Intervention type: OTHER
Intervention: Association of Myosin VI with oestrogen receptor
Description: 1. Gene expression analysis - RNA will be extracted from 100mg of tissue and then subjected to RT-qPCR to determine the relative expression levels of several genes, including MVI and ER Targets. We will use the same approach to determine which isoforms of MVI are expressed in the tissue.~2. Protein content analysis - Total protein will be extracted from 100 mg of tissue and western-blot analysis will be used to determine the relative amounts of MVI. Moreover, we will use cell fractionation to determine relative amounts of nuclear versus cytoplasmic protein.~3. Genomic analysis - Chromatin-immunoprecipitation (ChIP) experiments we be performed upon 100 mg of tissue sample. Here we will determine the localisation of MVI on the genome within the different tissues.
Study NCT03734016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 160 mg orally twice daily
Study NCT03734016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib
Description: Ibrutinib 420 mg orally once daily
Study NCT03220724 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505TF
Description: Administered by intramuscular (IM) injection in the thigh
Study NCT00295009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProDisc
Description: Total disc replacement with ProDisc
Study NCT00295009 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProDisc
Description: Total disc replacement with ProDisc
Study NCT00295009 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Fusion
Description: A circumferential fusion will be utilized as the control group in this study. The technique will consist of an interbody fusion procedure using commercially available femoral ring allograft. A posterior lateral fusion with autogenous iliac crest bone graft, combined with pedicle screw instrumentation.
Study NCT02147730 — intervention group
Intervention type: PROCEDURE
Intervention: regional anesthesia
Description: all patients receiving a regional anesthesia/analgesia technique
Study NCT02147730 — intervention group
Intervention type: PROCEDURE
Intervention: non-regional anesthesia
Description: all patients receiving other-than-regional anesthesia techniques
Study NCT02844244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training group
Description: The training workshop included two two-hour sessions. It focused on the enhancement of knowledge, attitude, and practice of peer health promoters on implementing community activities for the residents.
Study NCT03981094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: suspension
Study NCT03981094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: capsule
Study NCT03789318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1000 mg IV administered intraoperatively
Study NCT01533337 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Free dorsal digital flap
Description: The dorsal digital flap, including both dorsal branches of the proper digital nerves, was designed on the dorsum of the donor finger between the distal third of the proximal phalanx and the distal interphalangeal joint.
Study NCT01266252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be given maximal 72 hours. In case analgosedation is still needed after stop of the dexmedetomidine infusion, the treatment is switched to conventional analgosedation regimens.~Additional drugs are given to every inadequately sedated-painful patient (assessed by regular Comfort-neo and Numeric Rating Scale scoring). In case of oversedation or adverse drug events (hypotension, bradycardia), a downtitration (or stop) of the dexmedetomidine infusion is needed.
Study NCT00353808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [S,S]-Reboxetine
Study NCT04190407 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intravenous access
Description: A tourniquet was used to raise the vein for entry into the vein every 15 s after the ciliary reflex disappeared. If the patient showed no response to the tourniquet (movement, coughing, or laryngospasm), an experienced anesthesiologist entered a vein in the dorsum of one hand using a 22-24 gauge cannula.
Study NCT00726791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Patients receive high frequency rTMS applied to the motor cortex (M1 area). The treatment protocol consists of 10 sessions of rTMS. At each session, patients receive 30 stimulation trains (10 Hz, 4 sec, 100% motor threshold) with 26 sec inter-train interval, resulting in a total of 1200 pulses per session.
Study NCT00079391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Manipulated Peripheral Blood Stem Cell graft on Day 0. Target CD34+ dose 6 x10e6/kg, (range 3 to 8x10e6/kg) CD3+ dose fixed to 2 x 10e4/kg.
Study NCT03223922 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole brain radiation therapy
Description: Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy Genu-sparing whole brain radiation therapy (GS-WBRT) 30 Gy in 3 Gy per fraction
Study NCT02684058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib was available as 50 mg and 75 mg hard capsules and as 10 mg dispersible tablets for oral suspension. Dabrafenib was administered orally, twice daily, and was dosed based on age and weight Patients \< 12 years old and ≥ 16 kg were to be administered either the dabrafenib capsules or dabrafenib dispersible tablets for oral suspension (dose: 5.25 mg/kg/day) Patients ≥ 12 years old and ≥ 19 kg were to be administered either the dabrafenib capsules or dabrafenib dispersible tablets for oral suspension (dose: 4.5 mg/kg/day) Patients \< 12 years old and \< 16 kg were to be administered dabrafenib dispersible tablets for oral suspension (dose: 5.25 mg/kg/day) Patients ≥12 years old and \<19 kg were to be administered dabrafenib dispersible tablets for oral suspension (dose: 4.5 mg/kg/day)
Study NCT02684058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib
Description: Trametinib was available as 0.5 mg and 2 mg film-coated tablets and as 5.0 mg powder in bottle for oral solution (0.05 mg/ml after reconstitution with 90 ml water).Trametinib was administered orally, once daily in combination with the first daily dose of dabrafenib and was dosed based on age and weight.~Patients \<6 years old and \<26 kg were to be administered the trametinib oral solution (dose: 0.032 mg/kg/day) Patients \<6 years old and ≥26 kg were to be administered either the trametinib oral solution or trametinib tablets (dose: 0.032 mg/kg/day) Patients ≥6 years old and ≥10 kg \< 33 kg were to be administered the trametinib oral solution (dose: 0.025 mg/kg/day) Patients ≥6 years old and ≥33 kg were to be administered either the trametinib oral solution or the trametinib tablets (dose: 0.025 mg/kg/day)
Study NCT02684058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin was supplied locally as commercially available and labelled accordingly to comply with legal requirements of each country. Carboplatin was administered as one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy. Each maintenance cycle was 6 weeks, and consisted of 4 weeks of chemotherapy with 2 weeks of rest.~Induction: 175 mg/m\^2 as weekly intravenous (IV) infusion on weeks 1 to 4, and on weeks 7 to 10, on the same day as vincristine dosing Maintenance: 175 mg/m\^2 as weekly IV infusion over 60 minutes on weeks 1 to 4 of each cycle.
Study NCT02684058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine was supplied locally as commercially available and labelled accordingly to comply with legal requirements of each country. Vincristine was administered as one course of induction (10 weeks of chemotherapy with 2 weeks of rest), followed by 8 cycles of maintenance chemotherapy.~Induction: 1.5 mg/m\^2 as weekly IV bolus infusion (0.05 mg/kg if child is \<12 kg) (maximum dose of 2.0 mg) for 10 weeks.~Maintenance: 1.5 mg/m\^2 as weekly IV bolus infusion (0.05 mg/kg if child is \<12 kg) (maximum dose of 2.0 mg) on weeks 1 to 3 of each cycle, on the same day as carboplatin dosing.
Study NCT03478254 — intervention group
Intervention type: BIOLOGICAL
Intervention: Influenza vaccination
Description: Correct influenza vaccination status was considered in the following situation:~- Received at least one Influenza vaccine dose in the last year.
Study NCT03478254 — intervention group
Intervention type: BIOLOGICAL
Intervention: Pneumococcal vaccination
Description: Correct pneumococal vaccination status was considered if a subject received at least one of the following options:~* One pneumococcal conjugate vaccine (PCV) 13 dose in the last year.~* One PCV13 dose following a pneumococcal polysaccharide vaccine (PPSV) 23 dose between the following 8 weeks and 12 months.~* One PPSV 23 dose in the last 5 years.~* One PPSV23 dose in the last 5 years and a second PPSV23 dose at 5 years or PCV13 at 1 year.
Study NCT03478254 — intervention group
Intervention type: BIOLOGICAL
Intervention: Hepatitis B Virus (HBV) vaccination
Description: Correct Hepatitis B Virus (HBV) vaccination status was considered in the following situation:~.- Received at least three consecutive doses of HBV vaccine during six consecutive months.
Study NCT02720055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological workbook
Study NCT02720055 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Basic information workbook
Description: Basic rehabilitation information that represents current practice.
Study NCT04926610 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proactive clinical ethics consultation
Description: When the patients meet the initiation criteria of this study, the patients were randomly assigned to the intervention group (providing proactive clinical ethics consultation) and the routine care group (no proactive clinical ethics consultation) after obtaining the consent of the subjects.
Study NCT02066831 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedical coaching
Study NCT02066831 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telemedical coaching
Study NCT02066831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Study NCT02664311 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Jet Ventilation
Description: Patients are randomized to receive either jet or conventional ventilation during this study
Study NCT02664311 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional ventilation
Description: Conventional ventilator - control arm
Study NCT03220724 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505w53
Description: Administered by IM injection in the thigh
Study NCT03220724 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CH505w78
Description: Administered by IM injection in the thigh